33 results about "Botulinum toxin type C" patented technology

The invention relates to the technical field of a preparation method of a type A recombinant botulinum toxin, in particular to a type A botulinum toxin obtained by adopting a gene recombination technology, and the amino acid sequence of the type A botulinum toxin is consistent with the sequence of the type A botulinum toxin prepared by extracting and purifying a wild strain Clostridium botulinum. According to the technical scheme, the single-chain protein of the botulinum toxin A sequentially comprises a botulinum toxin A light chain or a modified botulinum toxin A light chain, a connecting region and a botulinum toxin A heavy chain. According to the scheme, the high-quality recombinant botulinum toxin A is obtained after the single-chain protein is subjected to fermentation, crude purification, enzyme digestion and fine purification. According to the technical scheme, the problems of complex process, long period, high safety risk and the like in the existing process for preparing the botulinum toxin A from the wild bacterial strain clostridium botulinum can be solved, and meanwhile, the problem that the amino acid sequence consistent with that of the botulinum toxin A prepared from the wild bacterial strain clostridium botulinum cannot be obtained through the existing gene recombination technology is solved.

The present disclosure relates to methods of producing a 900 kDa BoNT / A complex, wherein the method does not comprise a step of precipitation during the purification process. Further provided herein are methods of preparing a Clostridium botulinum working cell bank (WCB).

The present application relates to methods of treating or preventing infection-related immune conditions using compositions comprising IgM. In particular, the present application provides a method for treating immune complications resulting from infection in a patient in need thereof, characterized in that the method comprises administering a composition comprising IgM. In some embodiments, the treatment of immune complications is carried out by immunomodulation. Also provided is a method for immunomodulating an infection in a patient in need thereof, characterized in that the method comprises administering a composition comprising IgM. The present application also provides a composition comprising IgM for use in the treatment of sepsis and a composition comprising IgM for use in the treatment of immune complications resulting from infection. In some embodiments, the above-mentioned infection or sepsis results from E. coli, Pseudomonas aeruginosa, Staphylococcus aureus, Klebsiella pneumoniae, Streptococcus pneumoniae, Clostridium difficile, Clostridium botulinum, or a combination thereof.

The present invention relates to a culture medium composition for producing botulinum toxin, and more particularly, to a culture medium composition for culturing Clostridium species capable of producing botulinum toxin. The culture medium composition of the present invention comprises casein hydrolysate and at least one plant-derived proteose peptone selected from the group consisting of pea hydrolysate, cottonseed hydrolysate, and wheat gluten hydrolysate. When Clostridium botulinum is cultured using the culture medium according to the present invention containing plant-derived proteose peptone, casein hydrolysate, and minerals, the growth rate of the bacteria in the culture medium is higher than that in each of the currently used culture medium and the culture medium containing only plant-derived proteose peptone. In addition, when the culture medium of the present invention is used, it is possible to produce a high concentration of botulinum toxin by culturing the bacteria in a safe manner.

In one aspect, the invention relates to compounds useful as hybrid antibiotics, acting as both activators of the ClpP protease and inhibitors of RNA polymerase activity. Also disclosed are methods of using the disclosed compounds in the treatment of infectious diseases such as, for example, biofilm-mediated diseases and infectious diseases due to prosthetic joint infections, intracellular bacteria, and Gram-positive bacteria (e.g., Gram-positive bacteria selected from Bacillus anthracis, Bacillus cereus, Bacillus subtilis, Clostridium difficile, Clostridium tetani, Clostridium botulinum, Clostridium perfringens, Corynebacterium diphtheria, Enterococcus faecalis, Enterococcus faecium, Listeria monocytogenes, Listeria ivanovii, Micrococcus luteus, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus saprophyticus, Staphylococcus hyicus, Staphylococcus intermedius, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

The present invention relates to a culture medium composition for culturing Clostridium botulinum and a method for preparing botulinum toxin using the culture medium composition, wherein the culture medium composition comprises: potato peptone, yeast extract and glucose. According to the present invention, the culture medium is a culture medium excluding animal-derived products and major allergens, and induces a strain producing botulinum toxin to reach a maximum growth level in a short time, thereby having the effect of shortening the production time of the botulinum toxin production process and reducing the unit production cost.

The present invention relates to a culture medium composition for culturing Clostridium botulinum and a method for preparing botulinum toxin using the culture medium composition, wherein the culture medium composition comprises: potato peptone, yeast extract and glucose. According to the present invention, animal-derived products and major allergens are excluded from the culture medium, and the culture medium induces a strain producing botulinum toxin to reach a maximum growth level in a short time, shortens the production time in the botulinum toxin production process, and reduces the production cost.

Provided herein are compositions comprising Clostridium botulinum neurotoxin serotype A (BoNT / A) with improved stability. Such BoNT / A compositions are produced by a process comprising filtering a solution comprising BoNT / A with a filter that is not gamma-irradiated or a filter that contains no free radicals or a low amount of free radicals. Further provided herein are methods of producing compositions comprising BoNT / A by filtering a solution comprising BoNT / A with a filter that is not gamma-irradiated or a filter that contains no free radicals or a low amount of free radicals.

The present disclosure relates to Clostridium botulinum neurotoxin serotype A (BoNT / A) compositions with a plurality of 900 kDa Clostridium botulinum neurotoxin serotype A (BoNT / A) complex species. Provided herein are compositions comprising BoNT / A that have a low level of oxidation at specific methionine positions of 150 kDa BoNT / A. Further provided herein are methods of producing a composition comprising BoNT / A using a low temperature during the process of fermenting Clostridium botulinum bacteria

Disclosed are a medium composition for culturing Clostridium botulinum comprising a potato peptone, a yeast extract and glucose, and a method of preparing a botulinum toxin using the same. The medium excludes animal-derived products and major allergens, and enables the botulinum toxin-producing strain to reach the maximum growth level within a short time, thereby providing effects of shortening the production time and reducing the production cost in the botulinum toxin production process.

Provided herein are solid compositions comprising Clostridium botulinum neurotoxin serotype A (BoNT / A), human serum albumin (HSA) and sodium chloride (NaCl); wherein less than 34% of soluble HSA conta

Provided herein are solid compositions comprising Clostridium botulinum neurotoxin serotype A (BoNT / A) and human serum albumin (HSA), wherein the solid compositions comprise a low amount of HSA aggregates. Further provided herein are methods of producing solid compositions comprising BoNT / A and HSA by drying a solution comprising BoNT / A in a manner such that the solution does not undergo freezing during drying.

In one aspect, the invention relates to compounds useful as hybrid antibiotics, acting as both activators of the ClpP protease and inhibitors of RNA polymerase activity. Also disclosed are methods of using the disclosed compounds in the treatment of infectious diseases such as, for example, biofilm-mediated diseases and infectious diseases due to prosthetic joint infections, intracellular bacteria, and Gram-positive bacteria (e.g., Gram-positive bacteria selected from Bacillus anthracis, Bacillus cereus, Bacillus subtilis, Clostridium difficile, Clostridium tetani, Clostridium botulinum, Clostridium perfringens, Corynebacterium diphtheria, Enterococcus faecalis, Enterococcus faecium, Listeria monocytogenes, Listeria ivanovii, Micrococcus luteus, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus saprophyticus, Staphylococcus hyicus, Staphylococcus intermedius, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

The present disclosure relates to Clostridium botulinum neurotoxin serotype A (BoNT / A) compositions with a plurality of 900 kDa Clostridium botulinum neurotoxin serotype A (BoNT / A) complex species. Provided herein are compositions comprising BoNT / A that have a low level of oxidation at specific methionine positions of 150 kDa BoNT / A. Further provided herein are methods of producing a composition comprising BoNT / A using a low temperature during the process of fermenting Clostridium botulinum bacteria

The present invention relates to a method of purifying a non-toxic protein-removed Clostridium botulinum neurotoxin protein.

A composition comprising a Clostridium botulinum neurotoxin serotype A (BoNT / A) complex comprising a plurality of variant species, wherein the variant species comprises BoNT / A with a C-terminal trunca

The present invention relates to a culture medium composition for producing botulinum toxin, and more particularly to a culture medium composition for culturing Clostridium sp. strains capable of producing botulinum toxin. When a Clostridium botulinum strain is cultured using a culture medium comprising vegetable peptone, glucose, and yeast extract without animal-derived components, the growth rate of the strain is increased compared to existing culture media, and the strain can be safely cultured since animal-derived components are not included, thereby increasing the yield of botulinum toxin.

The present invention relates to a medium composition for producing botulinum toxin and, more specifically, to a medium composition for culturing Clostridium sp. strains capable of producing botulinum toxin. When a medium containing vegetable peptone, glucose, and yeast extracts and not containing animal-derived components according to the present invention is used for culturing Clostridium botulinum strains, the strain growth rate is increased compared to the existing mediums, and the strains can be safely cultured due to not containing animal-derived components, thereby increasing the productivity of botulinum toxin.

The invention relates to the technical field of food microorganisms, in particular to a long-acting slow-release antibacterial preparation targeting clostridium botulinum spores as well as a preparation method and application of the long-acting slow-release antibacterial preparation. The long-acting slow-release bacteriostatic preparation comprises a wall material and a core material, the core material comprises a lactic acid bacteria metabolite and a spore coating penetrant; the wall material is prepared from konjac glucomannan, tannic acid, polylysine salt and hyaluronic acid. By preparing a core material compound and embedding the core material compound in a wall material microcapsule, a three-layer action system of spore coating damage, skin layer degradation and core metabolism inhibition is constructed. The preparation can significantly improve the targeting and stability of antibacterial components, realizes complete substitution of nitrite in meat products, has the characteristics of safety, high efficiency and long acting, and conforms to the national food safety and health industrial policy.

Provided herein are compositions comprising a Clostridium botulinum neurotoxin serotype A (BoNT / A) complex comprising a 150 kDa BoNT / A. Said 150 kDa BoNT / A is in the form of a plurality of sequence variant species, wherein the plurality of sequence variant species comprises a 150 kDa BoNT / A sequence variant species with a C-terminal truncated light chain.

The present invention relates to the technical field of a method for preparing a recombinant botulinum toxin type A, and particularly relates to a botulinum toxin type A obtained by means of gene recombination technology, the amino acid sequence of which is identical to the sequence of botulinum toxin type A prepared by means of extraction and purification from a wild Clostridium botulinum strain. Provided is a single-chain protein of botulinum toxin type A, sequentially comprising: a light chain of botulinum toxin type A or a modified light chain of botulinum toxin type A, a linking region, and a heavy chain of botulinum toxin type A. The single-chain protein is subjected to fermentation, crude purification, enzyme digestion, and fine purification to obtain high-quality recombinant botulinum toxin type A. The present invention can solve the existing problems of complex process, long period, high safety risk and the like in the preparation of botulinum toxin type A by using wild Clostridium botulinum strains, and also solve the existing problem that the amino acid sequence of botulinum toxin type A prepared by means of gene recombination technology cannot be identical to that of botulinum toxin type A prepared by wild Clostridium botulinum strains.

The present invention relates to a method for purifying Clostridium botulinum toxin, comprising separating a non-toxin protein and an uncomplexed botulinum toxin protein, and performing a purification process of hydrophobic interaction and ion-exchange chromatography, thereby obtaining the uncomplexed botulinum toxin protein having high purity and increased yield. By using the botulinum purification method of the present invention, various industrial uses are possible and, in particular, botulinum toxin, which is in high demand in the pharmaceutical field, can be economically and highly-efficiently mass-produced, and thus can be effectively used in the industry.

The utility model discloses a filtering and sterilizing device for botulinum toxin, which relates to the technical field of botulinum toxin sterilizing and filtering and comprises a storage bottle, a liquid pump, a pressure valve, a membrane filter, a breaker, two liquid stopping clamps, three hoses and a collecting bottle. The three hoses are respectively a hose I, a hose II and a hose III, the hose I is connected between the output end of the storage bottle and the input end of the liquid pump, the hose II is connected between the output end of the liquid pump and the input end of the membrane filter, and the hose III is connected between the output end of the membrane filter and the input end of the collection bottle. In the process of filtering the botulinum toxin solution, the botulinum toxin solution can be in a closed environment in the whole process, and the risk that clostridium botulinum aerosol in the air pollutes the filtered solution in the thallus separation process can be effectively avoided, so that the condition that viable bacteria in the process of the section enter the process of the next section is effectively prevented, and the quality of the botulinum toxin solution is improved. The biological safety risk is reduced.

The invention provides a nano antibody for resisting a C-type botulinum toxin receptor binding domain and application of the nano antibody. The C-type botulinum toxin receptor binding domain is used as an antibody to immunize alpaca, RNA is extracted from mononuclear cells of the alpaca, and the nano antibody resisting the C-type botulinum toxin receptor binding domain is screened from the mononuclear cells by using a phage display library technology. The nano antibody provided by the invention can be specifically bound with a C-type botulinum toxin receptor binding domain, has high affinity, can effectively inhibit specific binding of C-type botulinum toxin and a target cell membrane, and can neutralize the C-type botulinum toxin to play a protective role. The nano antibody provided by the invention is expected to be applied to preparation of C-type botulinum toxin poisoning antidotes. Meanwhile, the nano antibody provided by the invention can be applied to qualitative and quantitative analysis and detection of C-type botulinum toxin as a capture antibody and a detection antibody.

The present disclosure relates to methods for preparing Clostridium botulinum working cell bank. Further provided herein are methods of producing a composition comprising a 900 kDa BoNT / A complex, said method comprising an acid precipitation step.

The present application relates to the preparation method of type A recombinant botulinum toxin technical field, specifically relates to the type A botulinum toxin obtained by gene recombination technology, the amino acid sequence is identical with the sequence of type A botulinum toxin prepared by wild strain Clostridium botulinum extraction and purification.The technical scheme provides a single chain protein of type A botulinum toxin, which comprises in sequence: type A botulinum toxin light chain or modified type A botulinum toxin light chain, connecting region, type A botulinum toxin heavy chain.The single chain protein of the scheme is obtained after fermentation, crude purification, enzyme cutting and fine purification High-quality recombinant type A botulinum toxin.The technical scheme can solve the problems of complex process, long cycle, high safety risk and the like of the existing type A botulinum toxin prepared by wild strain Clostridium botulinum, and solve the problem that the existing gene recombination technology cannot obtain the amino acid sequence identical with the type A botulinum toxin prepared by wild strain Clostridium botulinum.

The present invention relates to a culture medium composition for producing botulinum toxin, and more particularly, to a culture medium composition for culturing Clostridium species capable of producing botulinum toxin. The culture medium composition of the present invention comprises at least one plant-derived proteose peptone selected from the group consisting of pea hydrolysate, cottonseed hydrolysate, and gluten hydrolysate. When Clostridium botulinum is cultured using the culture medium according to the present invention containing plant-derived proteose peptone and minerals, the growth rate of the bacteria in the culture medium is about 1.5-2 times higher than that of the bacteria in the currently used culture medium. In addition, when botulinum toxin is produced by culturing the bacteria in the culture medium, infection of transmissible spongiform encephalopathy (TSE) and the like is prevented by blocking the introduction of animal-derived components.

A low acid beverage product such as e.g. coffee, cold brew coffee or nitro cold brew coffee product that is shelf stable for 180 days at refrigerated conditions including a sealed container having a liquid portion and a headspace. The liquid portion has the beverage with oxygen dissolved therein. A method of manufacturing the beverage includes dissolving oxygen and into a cold beverage and packaging the liquid beverage product with oxygen dissolved therein into a sealed container. The liquid beverage product also includes flavorings or sweeteners or milk products in the sealed container and remains free from Clostridium botulinum (C. bot).

Refrigerated Processed Foods of Extended Durability (KEPFED) with a pH value of at least 4.6 and whereby the REPFED at a temperature between 0° C. and 10° C. is free of vegetative Listeria monocytogenes and / or feacal streptococci and / or Clostridium Botulinum and Bacillus cereus which are killed and whereby the spores of said bacteria are at least fatally injured, such that the spores can no longer grow out vegetatively into the relevant bacteria. And a method (1) for preserving the aforementioned REPFEDs that are stored in refrigerators.

Provided herein are solid compositions comprising Clostridium botulinum neurotoxin serotype A (BoNT / A) and human serum albumin (HSA), wherein the solid compositions comprise a small amount of HSA aggregates. Further provided herein are methods for preparing solid compositions comprising BoNT / A and HSA by drying a BoNT / A-containing solution such that the solution does not freeze during drying.